Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC

Background: Osimertinib has been the standard of care in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We evaluated outcomes between osimertinib and first/second-generation (1G/2G) EGFR-tyrosine kinase inhibitors (TKIs) as first-line (1L), and investigated how T7...

Full description

Saved in:
Bibliographic Details
Main Authors: Y. Uehara, Y. Takeyasu, T. Yoshida, A. Tateishi, M. Torasawa, Y. Hosomi, K. Masuda, Y. Shinno, Y. Matsumoto, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
epidermal growth factor receptor (EGFR)-mutation
first/second-generation EGFR-TKI
osimertinib
real-world data
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000365
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949820124000365

Similar Items